ARMP

Armata Pharmaceuticals, Inc.

5.83 USD

Last updated Sep 5, 11:22 UTC

Yesterday HIGH

$5.84

Yesterday LOW

$5.48

52w HIGH

$16.34

52w LOW

$2.4

EPS

-0.27

PE

-21.59

Next Earnings

Nov 11, 2026

Overview News Government Trades Fundamentals

Armata Pharmaceuticals, Inc. stock is up 24.04% since 30 days ago. The next earnings date is Nov 11, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.42% of the previous 32 September’s closed higher than August.

Benzinga Newsdesk

Mon Jul 20, 2026

Armata Pharma Promotes David House To CFO

Executive Leadership UpdateArmata also announced the promotion of David House to Chief Financial Officer. Mr. House has served as the Company's Senior Vice President, Finance and Principal Financial Officer since
Benzinga Newsdesk

Mon Jul 20, 2026

Armata Announces Significant Clinical, Regulatory, Manufacturing And Operational Progress Supporting Advancement Of AP-SA02 Toward Planned Phase 3 Superiority Study For Adjunct Treatment Of Complicated Bacteremia

FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meetingFour AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing
Benzinga Newsdesk

Mon Jul 13, 2026

Armata Pharma Receives Agreement From FDA On Agreed Initial Pediatric Study Plan

Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patientsLOS ANGELES, July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP)
Benzinga Newsdesk

Tue Jun 23, 2026

Armata Pharma Receives Additional $2.5M Of Non-Dilutive DoD Funding Via Medical Technology Enterprise Consortium, Managed By Naval Medical Research Command

Supports Phase 3 readiness of AP-SA02Non-dilutive DoD funding totals $28.7M to dateLOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the
Benzinga Newsdesk

Wed May 13, 2026

Armata Pharmaceuticals Q1 EPS $(3.16) Misses $(0.38) Estimate, Sales $789.000K Up From $491.000K YoY

Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(3.16) per share which missed the analyst consensus estimate of $(0.38) by 731.58 percent. This is a 1480 percent decrease over losses of $(0.20) per share
Benzinga Newsdesk

Thu May 7, 2026

Armata Pharmaceuticals Granted FDA's Fast Track Designation For AP-SA02 To Treat Bacterial Infections

Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment
Benzinga Newsdesk

Mon May 4, 2026

Armata Pharmaceuticals shares are trading higher after the company announced a paper in Communications Biology.
Benzinga Newsdesk

Mon May 4, 2026

Armata Pharmaceutics Announces Publication Of Paper In 'Communications Biology,' A Peer-Reviewed Journal From Nature Portfolio

The publication, titled, "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection," describes the structure of phage P7-1, which is included in Armata's multi-phage cocktail,
Benzinga Insights

Fri Apr 24, 2026

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights

Tue Apr 21, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session